Condition
Stage 0is Bladder Urothelial Carcinoma
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Terminated2
Completed1
Active Not Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03091660Phase 3Active Not Recruiting
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT02808143Phase 1Completed
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT02494635Terminated
Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer
NCT02699853Not ApplicableTerminatedPrimary
Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
Showing all 4 trials